
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Take a quick look at everything you may have missed in May, including the top FDA approvals and latest clinical updates.
In this monthly recap, Contemporary Pediatrics reviews the most significant developments shaping pediatric practice and public health. Click each title below for full coverage.






